EASY CAR-T

EASY CAR-T refers to Chimeric Antigen Receptor T-cell therapies produced using the **EASY** (coacervate-based system for gene delivery) platform. Developed by researchers at Westlake University and Nanoportal Biotech, this technology utilizes mammalian protein-based coacervates that form spontaneously via liquid–liquid phase separation with nucleic acids to encapsulate and deliver genetic cargo (such as mRNA, sgRNA, or DNA) into immune cells. Unlike traditional methods that rely on viral vectors, lipid nanoparticles (LNPs), or electroporation, the EASY system offers a non-viral, low-toxicity, and highly scalable approach for engineering T cells, NK cells, and hematopoietic stem cells. In preclinical studies, EASY-generated anti-CD19 CAR-T cells demonstrated potent anti-tumor activity in Raji tumor models, matching the efficacy of virally modified counterparts while maintaining high cell viability and supporting multiplexed gene editing (e.g., knockout of TRAC, B2M, and PDCD1).

Other names

coacervate-based system for gene delivery